Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas C Behenna

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Chemistry (Weinheim an Der Bergstrasse, Germany)|March 1, 2013
Expanding insight into asymmetric palladium-catalyzed allylic alkylation of N-heterocyclic molecules and cyclic ketonesNathan B Bennett, Douglas C Duquette, Jimin Kim, et al.
Chemistry & Biology|September 3, 2002
Functional analysis of the lipoglycodepsipeptide antibiotic ramoplaninPredrag Cudic, Douglas C Behenna, James K Kranz, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2002
Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formationPredrag Cudic, James K Kranz, Douglas C Behenna, et al.
Journal of the American Chemical Society|October 30, 2012
The reaction mechanism of the enantioselective Tsuji allylation: inner-sphere and outer-sphere pathways, internal rearrangements, and asymmetric C-C bond formationJohn A Keith, Douglas C Behenna, Nathaniel Sherden, et al.
Beilstein Journal of Organic Chemistry|November 11, 2014
Formal total syntheses of classic natural product target molecules via palladium-catalyzed enantioselective alkylationYiyang Liu, Marc Liniger, Ryan M McFadden, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|November 16, 2011
Enantioselective decarboxylative alkylation reactions: catalyst development, substrate scope, and mechanistic studiesDouglas C Behenna, Justin T Mohr, Nathaniel H Sherden, et al.
Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Journal of Medicinal Chemistry|March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Chemistry (Weinheim an Der Bergstrasse, Germany)|March 1, 2013
Expanding insight into asymmetric palladium-catalyzed allylic alkylation of N-heterocyclic molecules and cyclic ketonesNathan B Bennett, Douglas C Duquette, Jimin Kim, et al.
Chemistry & Biology|September 3, 2002
Functional analysis of the lipoglycodepsipeptide antibiotic ramoplaninPredrag Cudic, Douglas C Behenna, James K Kranz, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2002
Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formationPredrag Cudic, James K Kranz, Douglas C Behenna, et al.
Journal of the American Chemical Society|October 30, 2012
The reaction mechanism of the enantioselective Tsuji allylation: inner-sphere and outer-sphere pathways, internal rearrangements, and asymmetric C-C bond formationJohn A Keith, Douglas C Behenna, Nathaniel Sherden, et al.
Beilstein Journal of Organic Chemistry|November 11, 2014
Formal total syntheses of classic natural product target molecules via palladium-catalyzed enantioselective alkylationYiyang Liu, Marc Liniger, Ryan M McFadden, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|November 16, 2011
Enantioselective decarboxylative alkylation reactions: catalyst development, substrate scope, and mechanistic studiesDouglas C Behenna, Justin T Mohr, Nathaniel H Sherden, et al.
Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Journal of Medicinal Chemistry|March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Pageof 2